Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Parallel-group Treatment, Phase 2, Double-blind Pilot Study to Investigate the Efficacy and Safety of Elinzanetant Compared With Placebo for Treatment of Sleep Disturbances Associated With Menopause.

NCT06112756 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT06112756
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06112756 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Parallel-group Treatment, Phase 2, Double-blind Pilot Study to Investigate the Efficacy and Safety of Elinzanetant Compared With Placebo for Treatment of Sleep Disturbances Associated With Menopause.
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
November 8, 2023
Completion date
November 7, 2024
Enrollment
110 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

sleep disturbances associated with menopause